[HIV vaccine: how far along are we?]

Area of Science:

• Immunology
• Vaccinology
• Virology

Background:

• Developing an effective human immunodeficiency virus (HIV) vaccine is a significant global health challenge.
• The high diversity and mutation rate of HIV necessitate a vaccine offering exceptionally broad protection.
• Decades of research underscore the complexity of eliciting a robust immune response against HIV.

Purpose of the Study:

• To review current strategies and future directions in HIV vaccine development.
• To highlight the need for broad-spectrum protection against HIV variants.
• To guide the optimization of vaccine candidates, excipients, and vaccination schedules.

Main Methods:

• Analysis of recent global clinical studies on HIV vaccine candidates.
• Review of strategies aimed at stimulating humoral (antibody) and cellular (T-cell) immunity.
• Synthesis of findings to inform future vaccine design and implementation.

Main Results:

• Current research focuses on stimulating either antibody production or T-cell immunity against HIV.
• An effective HIV vaccine likely requires the induction of both humoral and cellular immune responses.
• Sequential immunizations and combination strategies are being explored to achieve comprehensive immunity.

Conclusions:

• Broad and long-lasting protection against HIV is essential for an effective vaccine.
• Inducing both antibody and T-cell responses is crucial for comprehensive HIV immunity.
• Future HIV vaccine development will benefit from combining diverse immunotherapeutic strategies.